mRNA vaccines provide protection in clinical trials using a two-dose approach, separated by
a three to four week gap. UK policy in 2021 is to extend the dosing interval from three to
twelve weeks. There is a paucity of data in the elderly, even though these individuals are the
first to receive vaccines due to risk of severe disease. Here we assessed real world immune
responses following vaccination with mRNA-based vaccine BNT162b2. Methods We did a …